Quince Therapeutics, Inc.
QNCX
$30.32
$0.822.76%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 27.81M | 14.53M | 15.05M | 15.70M | 16.05M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 60.80M | 48.61M | 50.43M | 44.30M | 41.48M |
| Operating Income | -60.80M | -48.61M | -50.43M | -44.30M | -41.48M |
| Income Before Tax | -94.64M | -35.21M | -80.77M | -56.90M | -48.90M |
| Income Tax Expenses | -2.16M | -2.17M | 3.21M | 75.00K | 134.00K |
| Earnings from Continuing Operations | -92.48 | -33.04 | -83.98 | -56.98 | -49.03 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -92.48M | -33.04M | -83.98M | -56.98M | -49.03M |
| EBIT | -60.80M | -48.61M | -50.43M | -44.30M | -41.48M |
| EBITDA | -60.65M | -48.46M | -50.29M | -44.18M | -41.32M |
| EPS Basic | -125.55 | -182.00 | -328.71 | -243.91 | -219.53 |
| Normalized Basic EPS | -70.46 | -108.68 | -174.39 | -129.92 | -127.06 |
| EPS Diluted | -125.55 | -182.00 | -328.71 | -243.91 | -219.53 |
| Normalized Diluted EPS | -70.46 | -108.68 | -174.39 | -129.92 | -127.06 |
| Average Basic Shares Outstanding | 7.14M | 1.24M | 1.00M | 941.80K | 887.80K |
| Average Diluted Shares Outstanding | 7.14M | 1.24M | 1.00M | 941.80K | 887.80K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |